272 related articles for article (PubMed ID: 7847600)
1. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.
Mason BJ; Ritvo EC; Morgan RO; Salvato FR; Goldberg G; Welch B; Mantero-Atienza E
Alcohol Clin Exp Res; 1994 Oct; 18(5):1162-7. PubMed ID: 7847600
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
Mason BJ; Salvato FR; Williams LD; Ritvo EC; Cutler RB
Arch Gen Psychiatry; 1999 Aug; 56(8):719-24. PubMed ID: 10435606
[TBL] [Abstract][Full Text] [Related]
3. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
Karhuvaara S; Simojoki K; Virta A; Rosberg M; Löyttyniemi E; Nurminen T; Kallio A; Mäkelä R
Alcohol Clin Exp Res; 2007 Jul; 31(7):1179-87. PubMed ID: 17451401
[TBL] [Abstract][Full Text] [Related]
4. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
Mann K; Bladström A; Torup L; Gual A; van den Brink W
Biol Psychiatry; 2013 Apr; 73(8):706-13. PubMed ID: 23237314
[TBL] [Abstract][Full Text] [Related]
5. Nalmefene. Alcohol dependence: no advance.
Prescrire Int; 2014 Jun; 23(150):150-2. PubMed ID: 25121147
[TBL] [Abstract][Full Text] [Related]
6. Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.
Palpacuer C; Laviolle B; Boussageon R; Reymann JM; Bellissant E; Naudet F
PLoS Med; 2015 Dec; 12(12):e1001924. PubMed ID: 26694529
[TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
Gual A; He Y; Torup L; van den Brink W; Mann K;
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1432-42. PubMed ID: 23562264
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.
Higuchi S; Takahashi M; Murai Y; Tsuneyoshi K; Nakamura I; Meulien D; Miyata H
Psychiatry Clin Neurosci; 2020 Aug; 74(8):431-438. PubMed ID: 32359104
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.
van den Brink W; Sørensen P; Torup L; Mann K; Gual A;
J Psychopharmacol; 2014 Aug; 28(8):733-44. PubMed ID: 24671340
[TBL] [Abstract][Full Text] [Related]
10. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence.
Anton RF; Pettinati H; Zweben A; Kranzler HR; Johnson B; Bohn MJ; McCaul ME; Anthenelli R; Salloum I; Galloway G; Garbutt J; Swift R; Gastfriend D; Kallio A; Karhuvaara S
J Clin Psychopharmacol; 2004 Aug; 24(4):421-8. PubMed ID: 15232334
[TBL] [Abstract][Full Text] [Related]
11. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
Soyka M; Friede M; Schnitker J
Pharmacopsychiatry; 2016 Mar; 49(2):66-75. PubMed ID: 26845589
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.
van den Brink W; Strang J; Gual A; Sørensen P; Jensen TJ; Mann K
Expert Opin Drug Saf; 2015 Apr; 14(4):495-504. PubMed ID: 25652768
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
[TBL] [Abstract][Full Text] [Related]
14. Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial.
Miyata H; Takahashi M; Murai Y; Tsuneyoshi K; Hayashi T; Meulien D; Sørensen P; Higuchi S
Psychiatry Clin Neurosci; 2019 Nov; 73(11):697-706. PubMed ID: 31298784
[TBL] [Abstract][Full Text] [Related]
15. Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject.
Salvato FR; Mason BJ
Alcohol Clin Exp Res; 1994 Oct; 18(5):1187-9. PubMed ID: 7847604
[TBL] [Abstract][Full Text] [Related]
16. [Benefits in reducing alcohol consumption: how nalmefene can help].
Bendimerad P; Blecha L
Encephale; 2014 Dec; 40(6):495-500. PubMed ID: 25454365
[TBL] [Abstract][Full Text] [Related]
17. Opioid Receptor Antagonists in the Treatment of Alcoholism.
Serecigni JG
Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315
[TBL] [Abstract][Full Text] [Related]
18. Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.
Quelch DR; Mick I; McGonigle J; Ramos AC; Flechais RSA; Bolstridge M; Rabiner E; Wall MB; Newbould RD; Steiniger-Brach B; van den Berg F; Boyce M; Østergaard Nilausen D; Breuning Sluth L; Meulien D; von der Goltz C; Nutt D; Lingford-Hughes A
Biol Psychiatry; 2017 Jun; 81(11):941-948. PubMed ID: 28216062
[TBL] [Abstract][Full Text] [Related]
19. Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stevenson M; Pandor A; Stevens JW; Rawdin A; Rice P; Thompson J; Morgan MY
Pharmacoeconomics; 2015 Aug; 33(8):833-47. PubMed ID: 25851485
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies.
van den Brink W; Aubin HJ; Bladström A; Torup L; Gual A; Mann K
Alcohol Alcohol; 2013; 48(5):570-8. PubMed ID: 23873853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
